Lidokain Isdin (Lidocaine Cream 40 mg/g)
Topical local anesthetic for skin numbing and pain relief
Quick Facts: Lidokain Isdin
Key Takeaways
- Lidokain Isdin contains 4% lidocaine and is applied to intact skin to provide local numbing before procedures or for temporary surface pain relief.
- The cream typically takes 20 to 60 minutes to produce full anesthetic effect, and numbing can last 1 to 2 hours after removal.
- Do not apply to open wounds, broken skin, mucous membranes, or large body areas, as this increases the risk of systemic absorption and toxicity.
- Most side effects are local and mild (redness, slight swelling, tingling), but seek immediate medical help if you experience dizziness, blurred vision, or irregular heartbeat.
- Use cautiously in children, the elderly, and during pregnancy or breastfeeding — always under healthcare professional guidance.
What Is Lidokain Isdin and What Is It Used For?
Quick Answer: Lidokain Isdin is a topical cream containing 4% lidocaine, a local anesthetic that numbs the skin. It is prescribed for temporary pain relief before minor procedures and to alleviate localized surface pain on intact skin.
Lidokain Isdin belongs to the amide class of local anesthetics, with lidocaine as its active ingredient at a concentration of 40 mg/g (4%). Lidocaine is one of the most widely used local anesthetics in the world, having been in clinical use since the 1940s. It is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its established safety profile and therapeutic importance across healthcare systems globally.
The cream formulation is designed specifically for topical application to intact skin. When applied, lidocaine penetrates the outer skin layers and reversibly blocks voltage-gated sodium channels in sensory nerve fibers. This prevents the initiation and conduction of nerve impulses, effectively interrupting pain signal transmission from the application site to the brain. The result is a temporary loss of sensation (numbness) in the treated area.
Lidokain Isdin is commonly prescribed for several clinical indications. Before minor medical procedures — such as venipuncture (blood draws), intravenous cannulation, vaccination, or superficial skin surgery — the cream is applied to numb the skin and reduce procedural pain. It is also used to provide temporary relief from localized surface pain associated with minor skin conditions. In dermatological practice, it may be applied prior to procedures such as curettage, laser treatments, or needle-based cosmetic interventions.
The 4% concentration in Lidokain Isdin provides a balance between effective local anesthesia and minimal systemic absorption when used as directed on intact skin. Higher concentrations of lidocaine are available in other formulations (such as 5% patches or creams), but the 4% cream is suitable for the majority of topical applications. The cream base also helps to keep the medication in contact with the skin surface, allowing for gradual absorption and sustained local effect.
Mechanism of Action
Lidocaine works at the cellular level by binding to the intracellular portion of voltage-gated sodium channels in nerve cell membranes. When these channels are blocked, sodium ions cannot flow into the nerve cell, preventing the depolarization necessary to generate and propagate nerve impulses. This process is reversible — once the lidocaine is cleared from the tissue, normal nerve function returns completely.
The onset and depth of anesthesia depend on several factors: the amount of cream applied, the duration of application, whether an occlusive dressing is used to enhance absorption, and the specific area of skin being treated. Thinner skin areas (such as the inner wrist or behind the ear) tend to absorb lidocaine faster than thicker-skinned regions.
What Should You Know Before Using Lidokain Isdin?
Quick Answer: Before using Lidokain Isdin, inform your doctor about any allergies to local anesthetics, heart conditions, liver problems, or current medications. Do not use on broken skin. Special caution is needed during pregnancy, breastfeeding, and in children.
Contraindications
There are several situations in which Lidokain Isdin should not be used. Absolute contraindications include known hypersensitivity or allergy to lidocaine, other amide-type local anesthetics (such as bupivacaine, mepivacaine, prilocaine, or ropivacaine), or any of the excipients in the cream. Patients with a documented history of allergic reactions to these substances must avoid this product entirely.
The cream must not be applied to open wounds, cuts, abrasions, mucous membranes, or areas of broken or inflamed skin. Application to damaged skin dramatically increases the rate and extent of systemic lidocaine absorption, which can lead to toxic blood levels and serious adverse effects affecting the heart and central nervous system.
Lidokain Isdin should not be used near the eyes, as it may cause corneal irritation and temporary visual disturbance. It should also not be used in the ear canal if the tympanic membrane (eardrum) is perforated, as lidocaine reaching the middle ear can cause ototoxic effects.
Warnings and Precautions
Several groups of patients require special caution when using Lidokain Isdin. Individuals with severe hepatic (liver) impairment may have reduced ability to metabolize lidocaine, leading to higher plasma levels and an increased risk of toxicity. Lidocaine is primarily metabolized in the liver by the cytochrome P450 enzyme system (specifically CYP3A4 and CYP1A2), so any condition that impairs liver function can affect drug clearance.
Patients with cardiac conduction disorders, severe heart failure, or bradycardia should use this product with caution, as systemic lidocaine (even from topical absorption) can affect cardiac electrical conduction. While the systemic absorption from topical cream applied to intact skin is generally low, the risk increases if the cream is applied to large areas, left on for extended periods, or used on compromised skin.
Patients with epilepsy or other seizure disorders should be monitored carefully, as lidocaine in high systemic concentrations can lower the seizure threshold. Those with glucose-6-phosphate dehydrogenase (G6PD) deficiency should also be aware that the combination of lidocaine with certain other agents (notably prilocaine, sometimes found in combination anesthetic creams) can increase the risk of methemoglobinemia.
Seek immediate medical attention if you experience any of the following after applying Lidokain Isdin: dizziness, lightheadedness, blurred or double vision, ringing in the ears (tinnitus), numbness around the mouth or tongue, metallic taste, muscle twitching, tremors, difficulty breathing, confusion, or irregular heartbeat. These may indicate systemic lidocaine toxicity and require urgent medical evaluation.
Pregnancy and Breastfeeding
Lidocaine is classified as a Category B drug in pregnancy by the U.S. FDA, meaning animal reproduction studies have not demonstrated a fetal risk, but there are no adequate and well-controlled studies in pregnant women. Lidocaine crosses the placental barrier, and while topical application on a small area of intact skin results in minimal systemic absorption, the potential risks should be weighed against the benefits.
Pregnant women should use Lidokain Isdin only when clearly needed and when prescribed by a healthcare provider. The cream should not be applied to large body areas or used for prolonged periods during pregnancy, as this could increase fetal exposure.
Lidocaine is excreted in breast milk in small quantities. The amount reaching the infant through breast milk after topical application of the cream to a small skin area is expected to be negligible. However, breastfeeding mothers should consult their physician before use and avoid applying the cream to the breast area where the infant could have direct contact with it.
How Does Lidokain Isdin Interact with Other Drugs?
Quick Answer: Lidokain Isdin can interact with other local anesthetics (additive toxicity), class I and III antiarrhythmics, and CYP3A4/CYP1A2 inhibitors. While topical use generally results in low systemic absorption, interactions become clinically relevant when large areas are treated or multiple lidocaine products are used simultaneously.
Drug interactions with topical lidocaine cream are generally less clinically significant than those associated with injectable or oral lidocaine, because topical application to intact skin produces relatively low systemic levels. However, certain interactions warrant awareness and medical supervision, particularly in patients who are using multiple medications or applying the cream to large body areas.
Major Interactions
The most important interaction to be aware of is the additive effect when Lidokain Isdin is used alongside other products containing local anesthetics. Using multiple lidocaine-containing products simultaneously (for example, a lidocaine patch on the back and Lidokain Isdin cream on the arm) increases total systemic lidocaine exposure and the risk of toxicity. The combined dose from all sources should never exceed the recommended maximum.
Class I antiarrhythmic medications (such as mexiletine and tocainide) share a similar mechanism of action with lidocaine, as they also block sodium channels. Concurrent use can produce additive cardiac depressant effects. Similarly, class III antiarrhythmics (such as amiodarone) can interact with lidocaine, potentially increasing the risk of cardiac adverse effects.
Minor Interactions
Drugs that inhibit the CYP3A4 enzyme system (such as ketoconazole, itraconazole, erythromycin, and ritonavir) may decrease the hepatic metabolism of lidocaine, potentially leading to increased plasma concentrations. CYP1A2 inhibitors (such as fluvoxamine and ciprofloxacin) can have a similar effect. While these interactions are more relevant for systemic lidocaine administration, patients using these medications should inform their healthcare provider.
Beta-blockers (such as propranolol) can reduce hepatic blood flow, thereby decreasing the clearance of lidocaine and potentially increasing blood levels. Cimetidine, an H2-receptor antagonist, is also known to reduce lidocaine clearance. Patients taking these medications should be monitored for signs of lidocaine accumulation if using the cream on larger areas or for extended periods.
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Other local anesthetics (lidocaine patches, EMLA, prilocaine) | Additive toxicity | High | Do not exceed combined maximum dose; monitor for toxicity signs |
| Class I antiarrhythmics (mexiletine, tocainide) | Additive cardiac depression | Moderate to High | Use with caution; cardiac monitoring may be needed |
| Class III antiarrhythmics (amiodarone) | Additive cardiac effects | Moderate | Monitor heart rhythm; consult cardiologist |
| CYP3A4 inhibitors (ketoconazole, erythromycin, ritonavir) | Decreased lidocaine metabolism | Low to Moderate | Reduce application area or duration if using concurrently |
| Beta-blockers (propranolol) | Reduced hepatic clearance | Low | Monitor for signs of toxicity with extensive use |
| Cimetidine | Reduced hepatic clearance | Low | Consider alternative H2 blocker if lidocaine used extensively |
What Is the Correct Dosage of Lidokain Isdin?
Quick Answer: Apply a thick layer (approximately 1–2 g per 10 cm²) of Lidokain Isdin to the target area 30–60 minutes before the procedure. Maximum application area and duration depend on age and body weight. Always follow your healthcare provider's specific instructions.
The correct dosage of Lidokain Isdin depends on the clinical indication, the patient's age and weight, the area of skin being treated, and the duration of application. Because lidocaine has the potential for systemic absorption through the skin, it is important not to exceed the recommended dose, application area, or application time. The following guidelines represent general recommendations; your healthcare provider may adjust these based on your specific circumstances.
Adults
Standard Adult Dosage
Apply a thick layer of cream (approximately 1–2 g per 10 cm² of skin) to the treatment area. Cover with an occlusive dressing (such as plastic wrap) if directed by your healthcare provider. Leave the cream in place for 30 to 60 minutes for minor procedures, or up to 120 minutes for deeper procedures as instructed. Remove the cream and dressing before the procedure begins.
Maximum recommended dose: Do not apply to an area greater than 400 cm² (approximately 20 cm × 20 cm) at any one time. The maximum application time should not exceed 5 hours for intact skin. The maximum total dose per application should not exceed 60 g of cream (equivalent to 2,400 mg of lidocaine topically). In practice, much smaller amounts are typically sufficient.
Children
Pediatric Dosage
Lidocaine cream may be used in children under medical supervision, but the dose must be carefully adjusted according to the child's age and body weight. Children have thinner skin and a larger surface-area-to-weight ratio than adults, which increases the risk of systemic absorption.
- Neonates and infants up to 3 months (or under 5 kg): Maximum application area of 10 cm². Maximum application time of 1 hour. Use only under direct medical supervision.
- Infants 3–12 months (5–10 kg): Maximum application area of 20 cm². Maximum application time of 1 hour.
- Children 1–6 years (10–20 kg): Maximum application area of 100 cm². Maximum application time of 1–4 hours depending on the procedure.
- Children 6–12 years (over 20 kg): Maximum application area of 200 cm². Maximum application time of 1–4 hours.
- Adolescents over 12 years: Follow adult dosing guidelines with appropriate weight-based adjustments.
Elderly
Elderly Patients
Elderly patients may have thinner skin and reduced hepatic function, both of which can increase systemic lidocaine absorption and reduce clearance. While specific dose reductions are not always required, it is advisable to use the minimum effective amount, limit the application area, and reduce the application time. Healthcare providers may recommend shorter application periods (30–45 minutes) and closer monitoring for signs of systemic effects.
Missed Dose
Lidokain Isdin is typically used as a single application before a planned procedure, so the concept of a missed dose does not usually apply. If you forget to apply the cream before a procedure, apply it as soon as you remember, allowing sufficient time for it to take effect (at least 20–30 minutes). If there is not enough time for the cream to work, consult your healthcare provider about alternative pain management options.
Overdose
Lidocaine overdose from topical cream, while uncommon when used as directed, can occur if the cream is applied to excessively large areas, left on for too long, applied to broken or inflamed skin, or used in conjunction with other lidocaine-containing products. Symptoms of lidocaine overdose typically progress through two phases.
Initially, central nervous system (CNS) excitation may occur, with symptoms including restlessness, anxiety, lightheadedness, ringing in the ears, metallic taste, tingling or numbness around the mouth, blurred vision, and muscle twitching. If not recognized and treated, this may progress to CNS depression with drowsiness, seizures, loss of consciousness, and respiratory depression.
Cardiovascular effects of overdose include hypotension (low blood pressure), bradycardia (slow heart rate), and in severe cases, cardiac arrhythmias or cardiac arrest. If overdose is suspected, the cream should be removed immediately, and emergency medical assistance should be sought. Treatment is supportive and may include anticonvulsant therapy and cardiovascular support. Intravenous lipid emulsion therapy has been used in severe local anesthetic toxicity.
| Patient Group | Max Application Area | Max Duration | Special Notes |
|---|---|---|---|
| Adults (over 12 years) | 400 cm² | Up to 5 hours | Use occlusive dressing if directed |
| Children 6–12 years | 200 cm² | 1–4 hours | Weight-based assessment recommended |
| Children 1–6 years | 100 cm² | 1–4 hours | Medical supervision required |
| Infants 3–12 months | 20 cm² | 1 hour | Strict weight-based dosing |
| Neonates (<3 months) | 10 cm² | 1 hour | Only under direct medical supervision |
| Elderly | Reduced (individualized) | 30–60 minutes preferred | Consider reduced hepatic function |
What Are the Side Effects of Lidokain Isdin?
Quick Answer: Most side effects of Lidokain Isdin are local and mild, including temporary skin redness, swelling, and tingling at the application site. Serious systemic effects (dizziness, irregular heartbeat, seizures) are rare when used correctly on intact skin.
Like all medications, Lidokain Isdin can cause side effects, although not everyone experiences them. The vast majority of adverse reactions are local and self-limiting, occurring at the site of application and resolving once the cream is removed. Systemic side effects are uncommon when the product is used as directed on intact skin at recommended doses.
The frequency of side effects is classified according to the standard convention used in pharmacology: very common (affects more than 1 in 10 users), common (affects 1 in 10 to 1 in 100 users), uncommon (affects 1 in 100 to 1 in 1,000 users), and rare (affects fewer than 1 in 1,000 users). Understanding these categories helps patients assess the likelihood of experiencing a particular side effect.
Very Common
- Application site erythema (redness)
- Application site edema (mild swelling)
- Skin blanching (temporary paleness at the site)
Common
- Burning or stinging sensation upon application
- Pruritus (itching) at the application site
- Sensation of warmth or coolness at the site
- Skin irritation or dryness
Uncommon
- Contact dermatitis (allergic skin reaction)
- Urticaria (hives) at the application site
- Petechiae (tiny red spots) at the site
- Altered sensation (hypersensitivity or reduced feeling)
Rare
- Systemic allergic reaction (anaphylaxis)
- Dizziness, lightheadedness
- Tinnitus (ringing in the ears)
- Metallic taste in the mouth
- Blurred or double vision
- Muscle twitching or tremors
- Cardiac arrhythmias (irregular heartbeat)
- Methemoglobinemia (in predisposed individuals or with concurrent use of oxidizing agents)
Local reactions such as redness and mild swelling are a normal pharmacological response to lidocaine on the skin and do not necessarily indicate an allergy. These typically resolve within 1 to 2 hours after removal of the cream. However, if local reactions are severe, persistent, or worsen over time, discontinue use and consult a healthcare professional.
Contact emergency services immediately if you experience: severe allergic reaction (difficulty breathing, swelling of face/lips/tongue/throat, severe rash or hives all over the body), signs of systemic toxicity (seizures, severe dizziness, fainting, confusion, irregular or rapid heartbeat), or signs of methemoglobinemia (blue or grey discoloration of skin, lips, or nail beds, shortness of breath, fatigue, headache).
Healthcare providers should report any suspected adverse reactions to their national pharmacovigilance center. Patients can also report side effects directly through their country's adverse drug reaction reporting system, such as the Yellow Card Scheme in the UK, MedWatch in the USA, or the EudraVigilance system in the EU.
How Should You Store Lidokain Isdin?
Quick Answer: Store Lidokain Isdin at room temperature below 30°C, away from direct sunlight and heat. Keep the tube tightly closed. Do not freeze. Keep out of reach of children.
Proper storage of Lidokain Isdin is important to maintain the product's efficacy and safety throughout its shelf life. The cream should be stored at room temperature, ideally below 30°C (86°F). It should be kept away from direct sunlight, sources of heat, and high humidity environments. The bathroom medicine cabinet may not be ideal due to the humidity from bathing; a bedroom drawer or kitchen cupboard away from the stove is generally more suitable.
Do not freeze the cream, as freezing can alter the physical properties of the cream base and affect the uniform distribution of the active ingredient. After each use, ensure the tube cap is securely closed to prevent the cream from drying out and to protect it from contamination.
Keep Lidokain Isdin out of the reach and sight of children. Accidental ingestion of lidocaine cream by a child can cause serious adverse effects including numbness of the throat (which can impair swallowing and increase aspiration risk), seizures, and cardiac problems. If accidental ingestion occurs, seek medical attention immediately.
Do not use the cream after the expiry date printed on the tube and outer packaging. The expiry date refers to the last day of that month. Once opened, the cream should typically be used within the period stated on the packaging (check the open jar symbol for the "period after opening" guidance, often 6 to 12 months). Discard any remaining cream after this period.
Do not dispose of medicines via household waste or wastewater. Follow your local pharmacy's guidelines for medication disposal, or consult your pharmacist about how to properly discard unused or expired medications. This helps protect the environment.
What Does Lidokain Isdin Contain?
Quick Answer: The active substance is lidocaine at a concentration of 40 mg per gram of cream (4%). The cream base contains excipients that help deliver the medication to the skin, including emollients, stabilizers, and preservatives.
Each gram of Lidokain Isdin cream contains 40 mg of lidocaine as the active substance. This corresponds to a 4% weight-by-weight (w/w) concentration. Lidocaine (chemical name: 2-diethylamino-2',6'-acetoxylidide) is a synthetic amide-type local anesthetic with a molecular weight of 234.34 g/mol.
Active Ingredient
Lidocaine is the sole active pharmaceutical ingredient. It has been used in clinical medicine since 1948 and remains one of the most frequently used local anesthetics worldwide. In its topical cream formulation, lidocaine is incorporated into a cream base that allows it to penetrate the stratum corneum (the outermost layer of skin) and reach the sensory nerve endings in the dermis.
Excipients
The cream base of Lidokain Isdin contains various excipients (inactive ingredients) that serve specific pharmaceutical purposes. These may include emollients and emulsifiers to create the cream texture, humectants to maintain moisture, preservatives to prevent microbial contamination, pH adjusters to ensure stability, and thickening agents to provide the appropriate consistency. The exact composition of excipients may vary by market; consult the patient information leaflet supplied with your specific product for the complete list.
If you have known sensitivities or allergies to any excipients commonly found in topical creams (such as parabens, propylene glycol, cetyl alcohol, or stearyl alcohol), carefully review the full excipient list in the patient information leaflet before use. If in doubt, consult your pharmacist or healthcare provider.
The cream is a white to off-white, smooth, homogeneous preparation. It is supplied in aluminum or laminated tubes of various sizes (commonly 15 g, 30 g, or 50 g), depending on the market. Not all pack sizes may be marketed in every country.
Frequently Asked Questions
References
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023. Lidocaine listed as an essential local anesthetic.
- European Medicines Agency (EMA). Lidocaine — Summary of Product Characteristics. European public assessment reports. Available from: ema.europa.eu.
- U.S. Food and Drug Administration (FDA). Lidocaine — Drug Safety Communication: Serious Side Effects from Improper Use of Topical Numbing Products. FDA Drug Safety Communications, 2018.
- British National Formulary (BNF). Lidocaine Hydrochloride — Local Anaesthesia. National Institute for Health and Care Excellence (NICE). Updated 2024.
- Becker DE, Reed KL. Local Anesthetics: Review of Pharmacological Considerations. Anesthesia Progress. 2012;59(2):90–102. doi:10.2344/0003-3006-59.2.90.
- Tadicherla S, Berman B. Percutaneous Dermal Drug Delivery for Local Pain Control. Therapeutics and Clinical Risk Management. 2006;2(1):99–113.
- Zempsky WT. Pharmacologic Approaches for Reducing Venous Access Pain in Children. Pediatrics. 2008;122(Supplement 3):S140–S153. doi:10.1542/peds.2008-1055f.
- El-Boghdadly K, Pawa A, Chin KJ. Local Anesthetic Systemic Toxicity: Current Perspectives. Local and Regional Anesthesia. 2018;11:35–44. doi:10.2147/LRA.S154512.
- Association of Anaesthetists. Management of Severe Local Anaesthetic Toxicity — AAGBI Safety Guideline. 2020. Guidelines on lipid emulsion therapy for LAST.
- Taddio A, et al. Reducing Pain During Vaccine Injections: Clinical Practice Guideline. Canadian Medical Association Journal. 2015;187(13):975–982. doi:10.1503/cmaj.150391.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in dermatology, clinical pharmacology, and anesthesiology with documented academic backgrounds and extensive clinical experience.
Medical Review Board
All content reviewed according to international medical guidelines from WHO, EMA, FDA, and BNF. Evidence level 1A (systematic reviews and meta-analyses of RCTs). Following the GRADE evidence framework.
Editorial Standards
Independent medical information with no commercial funding or pharmaceutical sponsorship. All conflicts of interest are declared. Content is regularly updated to reflect the latest evidence and guidelines.